
Elasticity and Thermal Stability are Key Determinants of Hearing Rescue by Mini-Protocadherin-15 Proteins
Brief intro:
- Author: Pedro De-la-Torre, Haosheng Wen, Joseph Brower, Karina Martínez-Pérez, Yoshie Narui, Frank Yeh, Evan Hale, Maryna V. Ivanchenko, David P. Corey, Marcos Sotomayor and Artur A. Indzhykulian
- Journal: BioRxiv
- Doi: https://www.doi.org/10.1101/2024.06.16.599132
- Publication Date: 2024 Jun 17
Products/Services used in the paper
Quotation shows PackGene:AAVs for this study were produced by PackGene, Houston, TX. Serotype AAV9-PHP.B vectors were packaged in HEK293T cells using polyethylenimine-mediated cotransfection of the pAAV transfer plasmid, pHelper plasmid, and RepCap plasmid pUCmini-iCAP-PHP.B.
Research Field:hearing and balance
AAV Serotype:AAV9-PHP.B
Targeted organ:ear
Animal or cell line strain:mice
Abstract
Protocadherin-15 is a core protein component of inner-ear hair-cell tip links pulling on transduction channels essential for hearing and balance. Protocadherin-15 defects can result in non-syndromic deafness or Usher syndrome type 1F (USH1F) with hearing loss, balance deficits, and progressive blindness. Three rationally engineered shortened versions of protocadherin-15 (mini-PCDH15s) amenable for gene therapy have been used to rescue function in USH1F mouse models. Two can successfully or partially rescue hearing, while another one fails. Here we show that despite varying levels of hearing rescue, all three mini-PCDH15 versions can rescue hair-cell mechanotransduction. Negative-stain electron microscopy shows that all three versions form dimers like the wild-type protein, while crystal structures of some engineered fragments show that these can properly fold and bind calcium ions essential for function. In contrast, simulations predict distinct elasticities and nano differential scanning fluorimetry shows differences in melting temperature measurements. Our data suggest that elasticity and thermal stability are key determinants of sustained hearing rescue by mini-PCDH15s.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
